Our Pricing

How Wegovy Works: Private Prescription UK Access

Understanding how Wegovy works UK prescription pathways is essential before starting treatment. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural hormones to regulate appetite and blood sugar, helping patients achieve clinically significant weight loss when combined with lifestyle changes [1]. At Cured Pharmacy, you can access genuine UK-licensed Wegovy from £79.00 following a free online consultation with our registered prescribers.

How Wegovy Works: The Science Behind Semaglutide

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that works by mimicking the action of the naturally occurring GLP-1 hormone in your body [1]. When you eat, your intestines release GLP-1, which signals to your brain that you're satisfied, slows gastric emptying, and helps regulate blood sugar levels. Semaglutide amplifies these effects by binding to GLP-1 receptors throughout your body, particularly in areas of the brain that control appetite and food intake.

The medication works through three primary mechanisms: it reduces hunger by acting on appetite centres in the hypothalamus, delays stomach emptying so you feel fuller for longer after meals, and improves insulin secretion while reducing glucagon release [2]. This multi-pathway approach explains why clinical trials have demonstrated superior weight loss outcomes compared to lifestyle modification alone.

In the landmark STEP 1 trial, participants using Wegovy achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. Importantly, 83.5% of patients on semaglutide lost at least 5% of their body weight — the threshold considered clinically meaningful — demonstrating consistent efficacy across diverse patient populations.

Why GLP-1 Receptor Agonists Are Effective for Weight Loss

GLP-1 receptor agonists like semaglutide represent a significant advancement in obesity treatment because they address the biological mechanisms that make sustained weight loss difficult. Unlike appetite suppressants that work solely through the central nervous system, GLP-1 medications engage multiple physiological pathways simultaneously, creating a more comprehensive metabolic response [2].

Clinical experience from our superintendent pharmacist Tarun Kumar and our prescribing team shows that patients typically notice reduced food cravings within the first few weeks of treatment, with progressive weight loss becoming evident from week 4 onwards. The once-weekly injection schedule also supports better adherence compared to daily medications, contributing to improved long-term outcomes.

Wegovy Dosing Schedule and Treatment Timeline

Wegovy follows a structured dose escalation protocol designed to minimise gastrointestinal side effects while optimising weight loss outcomes. Treatment begins with a 0.25 mg weekly injection for the first month, gradually increasing every four weeks through 0.5 mg, 1 mg, and 1.7 mg doses, before reaching the maintenance dose of 2.4 mg weekly [3].

This gradual titration schedule is clinically important — it allows your body to adapt to the medication's effects on gastric emptying and appetite regulation, significantly reducing the likelihood of nausea, vomiting, or other gastrointestinal symptoms. Patients who attempt to increase doses too quickly often experience more pronounced side effects and may discontinue treatment prematurely.

Most patients reach the full 2.4 mg maintenance dose by week 17 of treatment. Clinical trials show that weight loss continues progressively throughout the first year, with the majority of weight reduction occurring between weeks 20 and 60 [1]. After reaching your target weight, ongoing treatment is typically required to maintain results, as discontinuation often leads to gradual weight regain.

Who Can Use Wegovy: Eligibility Criteria in the UK

In the UK, Wegovy is licensed by the MHRA for adults with a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [3]. Your prescriber will calculate your BMI during the online consultation and assess whether you meet the clinical criteria for treatment.

Certain medical conditions preclude Wegovy use. The medication is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, active gallbladder disease, severe gastrointestinal disease, or a history of pancreatitis [3]. Pregnant or breastfeeding women should not use Wegovy, and treatment should be discontinued at least two months before planned conception.

Our UK-registered prescribers conduct a comprehensive medical assessment before approving any prescription. This includes reviewing your weight history, previous weight loss attempts, current medications, and any contraindications. The consultation typically takes under three minutes to complete online, with same-day prescribing decisions in most cases subject to clinical approval.

Medical Conditions That May Affect Wegovy Suitability

Patients with type 2 diabetes require careful consideration, as semaglutide affects blood glucose levels and may necessitate adjustment of other diabetes medications, particularly insulin or sulfonylureas, to prevent hypoglycaemia [2]. If you're currently taking other diabetes medications, your prescriber will review these during your consultation and may recommend monitoring protocols or dose adjustments.

Individuals with a history of diabetic retinopathy should be aware that rapid improvements in blood glucose control have been associated with temporary worsening of this condition in clinical trials [3]. Your prescriber will assess this risk and may recommend additional ophthalmological monitoring if you have pre-existing retinopathy.

How Wegovy Works Compared to Other Weight Loss Treatments

While Wegovy represents one of the most effective pharmacological weight loss treatments available in the UK, understanding how it compares to alternatives helps inform treatment decisions. Saxenda, another GLP-1 receptor agonist containing liraglutide, requires daily injections and typically produces more modest weight loss — averaging 8% body weight reduction compared to Wegovy's 14.9% in head-to-head comparisons [1][4].

Orlistat, a lipase inhibitor available over the counter in lower doses, works through an entirely different mechanism by blocking fat absorption in the intestines. Clinical trials show average weight loss of 3-5% with orlistat, significantly lower than GLP-1 receptor agonists, though it may be appropriate for patients who cannot use injectable treatments or prefer oral medication [4].

Mounjaro, containing tirzepatide, is a dual GIP/GLP-1 receptor agonist that has demonstrated even greater weight loss in clinical trials — up to 22.5% body weight reduction in some studies [5]. However, it's currently licensed in the UK primarily for type 2 diabetes, with weight loss as a secondary benefit, and pricing typically exceeds that of Wegovy. Your prescriber will discuss which option aligns best with your clinical profile and treatment goals.

Common Side Effects and How to Manage Them

The most frequently reported side effects with Wegovy are gastrointestinal in nature, reflecting the medication's mechanism of slowing gastric emptying. In clinical trials, nausea occurred in approximately 44% of patients, vomiting in 24%, diarrhoea in 30%, and constipation in 24% [3]. These effects are typically mild to moderate, most pronounced during dose escalation phases, and tend to diminish over time as your body adapts.

Practical strategies can significantly reduce gastrointestinal symptoms. Eating smaller, more frequent meals rather than large portions helps accommodate slower gastric emptying. Avoiding high-fat, greasy, or heavily spiced foods during the initial treatment weeks reduces nausea risk. Staying well-hydrated and taking your injection on the same day each week at a consistent time helps maintain stable medication levels and predictable effects.

More serious but rare side effects include pancreatitis, gallbladder problems, and hypoglycaemia in patients taking concurrent diabetes medications [3]. Seek immediate medical attention if you experience severe, persistent abdominal pain that radiates to your back, as this may indicate pancreatitis. Regular monitoring by your prescriber, particularly during the first few months of treatment, helps identify any complications early.

When to Contact Your Prescriber

Contact your prescriber if you experience persistent vomiting that prevents you from keeping down fluids, as this can lead to dehydration and may require temporary dose reduction or treatment interruption. Similarly, if you develop symptoms of gallbladder disease — such as right upper abdominal pain, fever, or yellowing of the skin — medical evaluation is necessary.

Patients with diabetes should monitor blood glucose levels more frequently during the first few weeks of Wegovy treatment, as improved glucose control may necessitate adjustment of other diabetes medications to prevent hypoglycaemia [2]. Our clinical team at Cured Pharmacy provides ongoing support throughout your treatment journey, and you can contact us on (+44) 116 4646009 with any concerns.

Accessing Wegovy Through Cured Pharmacy: Your Private Prescription Pathway

Obtaining a private Wegovy prescription through Cured Pharmacy follows a straightforward, clinically rigorous process designed to ensure treatment safety and suitability. Begin by completing our online medical consultation, which takes under three minutes and covers your weight history, current medications, relevant medical conditions, and treatment goals. This assessment is reviewed by one of our UK-registered prescribers, who will determine whether Wegovy is appropriate for your individual circumstances.

Unlike some providers, we display transparent upfront pricing before you begin your consultation — Wegovy is available from £79.00, with no hidden fees or subscription charges. Once your prescription is approved, your medication is dispensed by our GPhC-registered pharmacy (registration number 9012511) and dispatched in 100% discreet packaging via next-day delivery to any UK address.

Our service includes ongoing clinical support throughout your treatment. You'll receive clear injection technique guidance, side effect management advice, and access to our pharmacy team for any questions that arise. As a UK-registered online pharmacy under the supervision of superintendent pharmacist Tarun Kumar (GPhC 2233073), we supply only genuine, UK-licensed medicines sourced through regulated pharmaceutical supply chains.

Repeat prescriptions are managed through your online account, with regular clinical reviews to monitor your progress and adjust treatment as needed. This comprehensive approach ensures you receive the same standard of pharmaceutical care you'd expect from a traditional pharmacy, with the added convenience of online access and competitive pricing guaranteed to be the lowest in the UK.

Why Choose Cured Pharmacy for Your Wegovy Prescription

Our commitment to transparent pricing, genuine UK-licensed medications, and accessible clinical support distinguishes Cured Pharmacy in the online pharmacy sector. Every prescription is reviewed by qualified UK prescribers who apply the same clinical standards as NHS practitioners, ensuring you receive safe, appropriate treatment tailored to your individual needs.

We understand that starting weight loss treatment represents a significant decision, often after years of unsuccessful attempts through diet and exercise alone. Our team has supported thousands of patients through their weight loss journeys, and we're here to provide the clinical expertise and ongoing support that contributes to successful outcomes.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
3. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency (MHRA). Retrieved from https://www.medicines.org.uk/emc/product/13799
4. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
5. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and individual results may vary. The efficacy data cited reflects outcomes from clinical trials and may not be representative of all patients. Side effects can occur — please read the patient information leaflet carefully and discuss any concerns with your prescriber.